Post Reply
7261-7280 of 10899
LP share!!!!!!!!!!!!!!!!!sell!!!!!!!!!!!
SO for the 2 days 7th and 8th April there were 2.876m shares in total naked short. Is this legal? I thought "buying-in" was to PUNISH the seller who has been caught selling without shares. This joker is rewarded with profits...Courage INDEED
gEez...to open a naked short position in today's context also require quite some form of courage...hehee~
allright ( Date: 08-Apr-2008 15:17) Posted:
|
Just heard from my broker that there was another 1033m shares NAKED SHORT and at 11.30 there was "buying-in" at .82.cts This SHORTIST joker is a brave man.
so the support that OCBC quoted is at $0.76-$0.78 ...currently looking at quite a lot of big sell downs ...thought the pullback will already weaken and should start to cheong upwards already..shall continue to observe the volume
| Time | Last | Volume | Buy/Sell |
| 10:22:36 | 0.795 | 10,000 | Buy Up |
| 10:22:24 | 0.795 | 349,000 | Sell Down |
| 10:15:50 | 0.795 | 50,000 | Sell Down |
| 10:07:09 | 0.795 | 100,000 | Sell Down |
| 10:05:59 | 0.795 | 5,000 | Sell Down |
| 10:04:26 | 0.795 | 111,000 | Sell Down |
| 10:01:11 | 0.795 | 50,000 | Sell Down |
| 10:01:07 | 0.795 | 100,000 | Sell Down |
| 10:00:10 | 0.800 | 10,000 | Buy Up |
| 10:00:05 | 0.800 | 10,000 | Buy Up |
| 09:59:04 | 0.800 | 13,000 | Sell Down |
| 09:58:38 | 0.800 | 500,000 | Sell Down |
Impossible ( Date: 07-Apr-2008 17:45) Posted:
|
miss some action today....haiz...was doing my ICT....cannot cheer for BIG..... cheong har....
OCBC Investment Research Pte Ltd
Temporary weakness - Last week Biosensors surged above the upwards trendline which connects the higher lows between Aug and Dec 07. - The formation of a bullish candlestick on 1 April on the back of strong volume indicates that Biosensors has a high probability of heading higher after its current pullback wanes. - The pullback we observed over the last few days has been on the back of gradually declining volume. This indicates that the slip in price would not persist for long as it is losing momentum. We expect the rebound to resume as the pullback finds support around the uptrend line. - The stochastic indicator has just cut downwards from inside the overbought region, suggesting that there could be little more downside to the pullback at this juncture; this would take the price close to the support level at the uptrend line. - We have observed that both the 50 and 200-day are converging close to the uptrend line, hence we feel the support around S$0.76 - 0.78 is fairly strong at this juncture, which should form the base for Biosensors to resume its rebound. - 1st resistance maintained at S$0.85 and subsequent resistance set at S$0.96.
http://www.remisiers.org/research//Technical%20Analysis%20-%20BioSensors%20-%20080407%20-%20OIR.pdf
BIG supporters, a good start for this burger on Mon. Hope it can maintain the momemtum. He he.
Very nice fibo retracement....touch 79c and bounce back up!
Hope it will break 85c tomorrow!!!
Nice closing :) Bull flag?
| 16:30:27 | 0.800 | 100,000 | SellDown |
| 16:29:44 | 0.800 | 50,000 | SellDown |
| 16:29:03 | 0.800 | 650,000 | SellDown |
| 16:28:00 | 0.805 | 20,000 |
Buy Up |
| 16:01:43 | 0.805 | 118,000 | Sell Down |
| 16:00:08 | 0.805 | 10,000 | SellDown |
| 15:59:59 | 0.805 | 20,000 | SellDown |
| 15:58:22 | 0.805 | 3,000 | SellDown |
| 15:58:17 | 0.805 | 10,000 | SellDown |
| 15:57:53 | 0.805 | 8,000 | SellDown |
| 15:57:52 | 0.805 | 30,000 | SellDown |
| 15:57:44 | 0.805 | 20,000 | SellDown |
| 15:57:17 | 0.805 | 28,000 | SellDown |
| 15:57:04 | 0.805 | 25,000 | SellDown |
| 15:57:00 | 0.805 | 20,000 | SellDown |
| 15:56:51 | 0.805 | 110,000 | SellDown |
| 15:56:48 | 0.805 | 15,000 | X |
| 15:56:39 | 0.805 | 100,000 | SellDown |
| 15:56:37 | 0.805 | 5,000 | SellDown |
| 15:56:34 | 0.805 | 45,000 | SellDown |
| 15:56:30 | 0.805 | 10,000 | Buy Up |
| 15:56:28 | 0.805 | 200,000 | Buy Up |
| 15:56:26 | 0.805 | 150,000 | Buy Up |
| 15:56:20 | 0.805 | 100,000 | Buy Up |
| 15:56:14 | 0.805 | 122,000 | SellDown |
| 15:55:48 | 0.810 | 5,000 | Buy Up |
| 15:55:46 | 0.810 | 3,000 | SellDown |
| 15:55:44 | 0.810 | 7,000 | Buy Up |
| 15:55:42 | 0.810 | 3,000 | SellDown |
| 15:55:39 | 0.810 | 12,000 | SellDown |
| 15:55:37 | 0.810 | 10,000 | SellDown |
| 15:55:17 | 0.810 | 20,000 | SellDown |
| 15:55:02 | 0.810 | 777,000 | BuyUp |
| 15:54:30 | 0.805 | 968,000 | BuyUp |
| 15:53:36 | 0.800 | 460,000 | BuyUp |
| 15:52:58 | 0.800 | 5,000 | Buy Up |
| 15:43:17 | 0.800 | 10,000 | Buy Up |
| 15:40:47 | 0.800 | 10,000 | Buy Up |
| 15:19:05 | 0.800 | 10,000 | Buy Up |
Quite fierce buy-ups eh??? Brokerage buying in for the naked shortists???
The "BUYIN-IN" was for 1.843m shares done at .80 to .81cts. The naked short was prob done on the 2nd April ? which ranged from .805 to .85. Wow this shortist made money... I am just making a guess as I am inexperienced. Anyone can explain why anyone would be so brave OR as I wrote earlier- a genuine mistake?? If so a ...lucky mistake then
OOPS I meant "BUYING -IN" but somehow didn't appear. So was the short a genuine mistake? Any comments?
WOW!!! My broker just informed me that last week someone naked short $1.8m(may be more because they are still putting it out in batches) and they have been doing the stock exchange "buying -in" at .80 to .81. So was this a mistake or a clever shortist?
|
DJ MARKET TALK: Biosensors +2.5%; Technicals Bullish - OCBC (2008/04/07 09:59AM) |
The current CFO used to be working for Medtronic. The new CEO used to be working for Terumo. I suspect there could be some kind of "very top level" takeover arrangement that we are not aware but this is just my wild guess. Before you want to spend billions to buy up a company, wouldn't it be better to send someone you trust to work in the target campany in a key position to check out the "vital stats" very carefully before you make an offer? Surely you wouldn't want takeover disasters like what happended to JNJ when they bought Conor to happen to you right? Becareful there are many costemic make-overs like fake nose job, fake boobs job, etc. So many cosmetic jobs around in companies, you must make sure you get the real stuff and what you really paid for. If they spend US$2.5B, they must make sure this acquisition will make them US$10B eventually.
Old but interesting article: http://www.touchbriefings.com/pdf/3008/Ge.pdf
So many types of limus drugs: Biolimus, Sirolimus, Everolimus, Zotarolimus, Tacrolimus, Primecrolimus.
So many types of biodegradable polymers....... but PLA is the best and safest.
Even Biotronik ProGenic using Primecrolimus and PLA biodegradable polymer will be caught in BIG's patent (BIG's 11th trump card???)
I believe BIG's patent still have another 15 years duration. Anybody using any form of limus drugs on any form of biodegradable polymer will be caught in BIG's patent. So many matrix combination of any limus drugs on any type of biodegradable polymers. This is what i call very wide patent fencing. The wider the patent fencing, the more valuable because more people will be caught. One fine day these guys have to pay BIG huge sum of settlement money plus royalties for patent infringement. It is only a matter of time and the time will happen when these new DESs get regulatory approval (usually CE Mark).
Why these DES competitors know about the patent breach but continue to develop their DES? Because they believe they can pay-off BIG for patent breach eventually. Apple (MP3) breached Creative Technology's patent but they eventually paid Creative US$100m plus give Creative some sub-contract deals as patent breach settlement. Apple's iPhone (name) also infringed someone's trademark but Apple went ahead. Its all about dollars and cents when it comes to settlement. Same theory for DES. These guys will pay BIG off for patent breach eventually. Its a matter of time only. BIG just need to wait, see, sue and collect huge lump sum settlement and future royalties. However, this method of paying off money as settlement only applies if BIG remains as an independent company. If BIG is taken over by a big DES rival like JNJ or MDT, the whole equation changes completely. Paying off such MNCs for patent breach most likely will not work. So there is a very much added motivation for large DES players to buy over BIG....... to control this key patent, to wipe off so many rivals that are alreadying clearly in breach of this patent, to arm-twist top-class but smaller rivals that have breached this patent to sell their company to you at a distressed price so you can maintain market dominance. This is the real power of BIG's patent. Whoever holds this key patent will eventually be the most dominant DES player in the world.
JWMS Excel Biodegradable Polymer DES has pretty good clinical trial results. One thing I don't understand is that why did WeiGao want to sell it away. With these results, they could break into many existing markets, beside those 3rd world. Some more with their cheap production cost, they can easily marked down 30% lower than many others DES.
Perhaps, as what Bengster68 said, they might have some hidden reasons. One of them could be to prevent other competitors (e.g J&J) from buying over BIG!
------------------------------------------------------------------------------------------------
March 31, 2008 By Vijayalakshmi Kunadian MBBS MD MRCP [1]
SCAI-ACCi2 08-Chicago, IL: The 12 month clinical outcome of a prospective multicenter registry of Excel? biodegradable polymer sirolimus eluting stents suggests that these stents are safe and effective in the ?real world? population.
Dr. Yaling Han presented the results at the SCAI-i2 summit Annual Scientific Sessions in Chicago today. This presentation was followed by a commentary by Dr. John Ormiston from Auckland New Zealand.
The investigators in the CREATE (Multi-Center Registry of Excel BiodegrAdable Polymer Drug EluTing StEnt) study determined the safety and efficacy of a novel biodegradable polymer based sirolimus eluting stent (ExcelTM). The polymer on the stent is completely degraded within 6 months.
This Prospective, multi-center, post-marketing surveillance registry consisted of 2077 unselected ?real world? patients, of which 386 (18.6%) had an acute infarction during the preceding 24 hours. Patients were treated with dual antiplatelet therapy for 6 months. Patients were excluded if hybrid stenting was planned, had contraindications to dual antiplatelet therapy, severe congestive heart failure (NYHA class IV) and planned surgery in the near future.
The primary endpoint of this study consisted of major adverse cardiac events including cardiac death, myocardial infarction and target lesion revascularization (TLR). The secondary endpoints consisted of MACE at 1 and 6 months, late loss, binary restenosis and thrombotic events.
The incidence of MACE at 30 days, 6 months and at one year was low (0.9% vs. 1.8% vs. 2.7%). At 9 month angiographic follow-up, the overall in-stent late loss was 0.21±0.39 and the in-stent binary restenosis rate was 3.8%. However the in-stent (8.1% vs. 2.7%, p<0.001) and in-segment (11.2% vs. 5.5%, p=0.005) binary restenosis rate was greater with off label use compared with on label use among patients with long lesions. The in-segment binary restenosis was also greater in small vessels (10.3% vs. 5%, p=0.002).
Thrombotic events occurred in 0.82% of patients during one year follow-up. There was no difference in the overall MACE between off label and on label use of the stent (3% vs. 1.2%, p=0.081) but the TLR rate tended to be high in the off label cases (1.8% vs. 0.3%, p=0.049) with no difference in the incidence of stent thrombosis (0.8% vs. 0.63%, p=0.1).
The investigators in the study concluded that the use of ExcelTM biodegradable polymer coated sirolimus eluting stents is safe and effective in reducing restenosis similar to the results from the DES trials with dual antiplatelet therapy for 6 months. Further long term results are awaited.
Ha Ha....Bengser68, as what you have predicated this JADE is going to collapse on Monday.
? Target Price $0.05
|
bengster68
Veteran |
Posted: 21-Feb-2008 10:01 |
 x 0
 x 0
|
Jade's takeover is very fishy. Only a one page offer. Never seen takeover offer so brief and fishy. OCBC adviser??? Need to borrow a bank's name to have more credibility. Antony Soh brought in the deals to Jade to share with all the rest of the shareholders. Now he wants to spend over $100m privatise jade. What kind of bird deal maker will do such things? If Im Antony Soh i will use my own private company if the coal servicing deal and oil refinery deal is so fantastic. FYI Jade is doing the coal mining servicing only. That means they are doing the sub-contractor job. No experience in coal mining and need to buy mining machineries which can be very costly. The coal mine is owned by another party . This counter is highly manipulated. Look at the buy queue: Almost 400,000 lots queue to buy and a few thousand lots queue to sell. It gives an illusion that a lot of buyers want to buy. When this whole deal don't go thru, see the share price collapse again. The zhengkay will control the timing of when the deal will collapse. The zhengkays behind Jade must be quietly selling of Jade now. When they finish selling off most of their Jade shares, the takeover deal will then collapse and share price drop below 10cts again. Jade is one big kelong company not worth more than 3cts eventually. |